Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARGARET VON MEHREN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1144243858
CMS profile
233516
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,481.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,480.00 2
Food and Beverage $1.32 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,980.00 1
PFIZER INC. $1,501.32 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARGARET VON MEHREN

NPI 1144243858 · CMS profile ID 233516

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,481.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0005/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686543021 CMS
PFIZER INC. $1,500.0001/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673757429 CMS
PFIZER INC. $1.3201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673262617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,481.32 3
PY2022 $16,889.37 14
PY2024 $17,850.01 21
PY2025 $107.49 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $439.96 2
PY2025 Principal investigator $3,999,133.04 151
PY2024 Principal investigator $2,114,235.16 59
PY2023 Principal investigator $1,626,861.83 207
PY2022 Recipient $12,046.00 1
PY2022 Principal investigator $1,964,612.75 261
PY2021 Principal investigator $4,056,403.36 219
PY2020 Recipient $1,210.00 1
PY2020 Principal investigator $2,320,213.22 69
PY2019 Principal investigator $1,242,313.06 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

262 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $121,020.00 12/22/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953502811
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 12/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 965505581
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501851
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501863
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501869
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501879
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501885
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501889
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501893
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501898
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501903
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501907
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501919
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501925
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,621.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501929
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,526.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501935
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501939
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501945
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501949
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501955
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501961
Principal investigator 1 Deciphera Pharmaceuticals Inc. $454.00 12/06/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953501967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501097
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501101
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501107
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501113
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501119
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 12/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953501125
Recipient Eli Lilly and Company $12,046.00 11/29/2022 Covered Recipient Physician A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA No dispute reported 06/30/2026 917807581
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 11/22/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466059
Principal investigator 1 Deciphera Pharmaceuticals Inc. $145,224.00 11/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953500287
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/08/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 943972519
Principal investigator 1 GlaxoSmithKline, LLC. $1,340.00 11/08/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 943972523
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 11/08/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 943972529
Principal investigator 1 GlaxoSmithKline, LLC. $21,000.00 11/08/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 943972533
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,658.46 10/21/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466051
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497509
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497515
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497525
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497531
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497537
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,637.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497543
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497549
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497559
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497565
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,802.56 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497571
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497575
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497581
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497587
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497593
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497599
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497605
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497611
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497617
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,197.50 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497627
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 09/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953497633
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 09/01/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 943972539
Principal investigator 1 Deciphera Pharmaceuticals Inc. $128.00 08/27/2022 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953495879
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,417.00 07/07/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953491543
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490855
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490861
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490867
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490873
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490879
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,637.00 07/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 953490883
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489273
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489313
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489325
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489331
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489341
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489365
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 06/10/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953489375
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,250.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465991
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465999
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466009
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466017
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466027
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466033
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 05/27/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953466043
Principal investigator 1 Deciphera Pharmaceuticals Inc. $117,330.00 05/26/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953487875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,417.00 05/26/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953487887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $188.64 05/24/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465971
Principal investigator 1 Deciphera Pharmaceuticals Inc. $188.64 05/24/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465981
Principal investigator 1 Novartis Pharmaceuticals Corporation $235,968.31 05/03/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER FOX CHASE CANCER CENTER
AN OPEN LABEL MULTI CENTER IMATINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED IMATINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED IMATINIB TREATMENT No dispute reported 06/30/2026 909401047
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 04/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953486881
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 04/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953486955
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 04/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953487179
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 04/30/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953487541
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464859
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464867
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464883
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464891
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464899
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464907
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464917
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464925
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464935
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464943
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464951
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464961
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464969
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464977
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464987
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464997
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,831.38 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465003
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465013
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465021
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465029
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465039
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465045
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465055
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465063
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465073
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465083
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465089
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465099
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465107
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465117
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465123
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465133
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465141
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465150
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465157
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465167
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465175
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465181
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465191
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465199
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,831.38 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465209
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465216
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465223
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465233
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465239
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465247
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465257
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465265
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465275
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465283
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465293
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465301
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465311
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465319
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465329
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465337
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465347
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465355
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465363
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465373
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465381
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465391
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465399
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465407
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465415
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465425
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465436
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465443
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465451
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465459
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465469
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465477
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465483
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465493
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465501
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465511
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465529
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465537
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465546
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465563
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465571
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465581
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465589
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465597
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465605
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465615
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465631
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465639
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465647
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465655
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465665
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465673
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465683
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465701
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465709
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465719
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465727
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465737
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465745
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465753
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465761
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465771
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465779
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465791
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465797
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465808
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465817
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465827
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465837
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465845
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465862
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465871
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465879
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465897
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465905
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465914
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465923
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465931
Principal investigator 1 Deciphera Pharmaceuticals Inc. $943.20 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465939
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465947
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465957
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 04/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953465963
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 04/26/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953485201
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 04/26/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953485223
Principal investigator 1 Deciphera Pharmaceuticals Inc. $117,330.00 04/14/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953484847
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,417.00 04/14/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953484852
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464631
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464639
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464655
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464665
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464675
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464683
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464699
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464707
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464715
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464725
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464731
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464741
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464749
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464761
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464767
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464775
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464783
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464793
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464801
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464811
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464819
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464827
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464835
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 03/29/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 03/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953483051
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 03/05/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953483297
Principal investigator 1 Deciphera Pharmaceuticals Inc. $117,330.00 03/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953482335
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,417.00 03/03/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953482347
Principal investigator 1 Karyopharm Therapeutics Inc. $250.00 02/14/2022 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) No dispute reported 06/30/2026 956553241
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 02/14/2022 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) No dispute reported 06/30/2026 956553245
Principal investigator 1 Deciphera Pharmaceuticals Inc. $111,900.00 01/20/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953480845
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,417.00 01/20/2022 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 953480851
Principal investigator 1 Deciphera Pharmaceuticals Inc. $201,420.00 01/12/2022 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 953464621
Principal investigator 1 Novartis Pharmaceuticals Corporation $285,308.18 01/12/2022 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE
PHASE II TRIAL OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS IN ADVANCED DEDIFFERENTIATED LIPOSARCOMA DDL AND LEIOMYOSARCOMA LMS No dispute reported 06/30/2026 909396971